About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Sf3b1tm1.1Mdf
targeted mutation 1.1, Mark D Fleming
MGI:5818977
Summary 2 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
 		Sf3b1tm1.1Mdf/Sf3b1+
Tg(Mx1-cre)1Cgn/? 		involves: 129S4/SvJae * C57BL/6 * CBA/J MGI:5823482
cn2
 		Sf3b1tm1.1Mdf/Sf3b1+
Tet2tm1.1Iaai/Tet2tm1.1Iaai
Tg(Mx1-cre)1Cgn/? 		involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA/J MGI:5823559


Genotype
MGI:5823482
cn1
Allelic
Composition		 Sf3b1tm1.1Mdf/Sf3b1+
Tg(Mx1-cre)1Cgn/?
Genetic
Background		 involves: 129S4/SvJae * C57BL/6 * CBA/J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Sf3b1tm1.1Mdf mutation (2 available); any Sf3b1 mutation (74 available)
Tg(Mx1-cre)1Cgn mutation (7 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
hematopoietic system
abnormal erythropoiesis ( J:234976 )
• block in erythroblast development resulting in an increase in cells at development stage R2 and a decrease in R4 cell population in spleen and bone marrow 64 weeks post-piPC
abnormal myelopoiesis ( J:234976 )
• transplantation of bone marrow from mutants into lethally irradiated CD45.1 recipient mice that were treated with pIPC results in lower peripheral blood chimerism
• chimerism is lower in LT-HSC to committed myeloid progenitors
• increase in long term repopulating hematopoietic stem cells (LT-HSC) in bone marrow 45 and 64 weeks post-piPC treatment, however, repopulating ability is decrease
• decrease in percentage of granulocyte/monocyte progenitors
hypochromic macrocytic anemia ( J:234976 )
• progressive macrocytic anemia develops following pIPC injection
• anemia is present 4-8 weeks post-injection and is severe by 20 weeks
impaired hematopoiesis ( J:234976 )
• lower percentage of hematopoietic and stem progenitor cells in G1 and a higher percentage in G0 in vitro (24 weeks post-pIPC) as compared to control
decreased granulocyte monocyte progenitor cell number ( J:234976 )
• decrease in percentage of granulocyte/monocyte progenitors in aged mice
abnormal erythroid progenitor cell morphology ( J:234976 )
• increase in erythroid precursors in spleens is observed at 64 weeks post-pIPC
• erythroid dysplasia in spleens is observed at 47 weeks post-pIPC
decreased erythrocyte cell number ( J:234976 )
• total red blood cell number is decreased beginning at 20 weeks post-pIPC injection
• no differences in total white blood cell count, mature white blood cell lineages or platelet counts
increased mean corpuscular volume ( J:234976 )
• beginning at 20 weeks post-pIPC injectio
macrocytosis ( J:234976 )
• macrocytosis is apparent at 20 weeks post-pIPC injection
increased hematopoietic stem cell number ( J:234976 )
• increase in long term repopulating hematopoietic stem cells (LT-HSC) in bone marrow 64 weeks post-piPC treatment, however, repopulating ability is decreased
• no differences in short-term hematopoietic stem cells, multi potent progenitors, common myeloid progenitors, megakaryocytic/erythroid progenitors or colony forming units at 64 weeks post-pIPC
• increase in multi-potent progenitors (MPP) in bone marrow at 12 weeks, but not 45 weeks post-piPC treatment

homeostasis/metabolism
increased circulating erythropoietin level ( J:234976 )
• plasma erythropoietin levels are increased and persist for longer than 60 weeks post-pIPC as compared to wild-type

immune system
abnormal myelopoiesis ( J:234976 )
• transplantation of bone marrow from mutants into lethally irradiated CD45.1 recipient mice that were treated with pIPC results in lower peripheral blood chimerism
• chimerism is lower in LT-HSC to committed myeloid progenitors
• increase in long term repopulating hematopoietic stem cells (LT-HSC) in bone marrow 45 and 64 weeks post-piPC treatment, however, repopulating ability is decrease
• decrease in percentage of granulocyte/monocyte progenitors

mortality/aging
premature death ( J:234976 )
• 2 mice (18%) die by 64 weeks post piPC no wild-type mice die during this time




Genotype
MGI:5823559
cn2
Allelic
Composition		 Sf3b1tm1.1Mdf/Sf3b1+
Tet2tm1.1Iaai/Tet2tm1.1Iaai
Tg(Mx1-cre)1Cgn/?
Genetic
Background		 involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA/J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Sf3b1tm1.1Mdf mutation (2 available); any Sf3b1 mutation (74 available)
Tet2tm1.1Iaai mutation (2 available); any Tet2 mutation (779 available)
Tg(Mx1-cre)1Cgn mutation (7 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
hematopoietic system
enlarged spleen ( J:234976 )
• post-piPC treatment
abnormal erythropoiesis ( J:234976 )
• block in erythroblast development results in an increase in cells at development stage R2 and a decrease in R4 population in spleen by 12 weeks post-piPC
abnormal myelopoiesis ( J:234976 )
• transplantation of bone marrow from mutants into lethally irradiated CD45.1 recipient mice that were treated with pIPC results in increasing (46.5% to 90%) donor chimerism beginning at 16 weeks post transplantation as compared to mice carrying only the Sf3b1tm1.1Mdf allele and wild-type
hypochromic macrocytic anemia ( J:234976 )
• progressive macrocytic anemia 45 weeks post pIPC treatment
abnormal megakaryocyte morphology ( J:234976 )
• spleens contain dysplastic megakaryocytes 45 weeks post-piPC treatment
abnormal erythroid progenitor cell morphology ( J:234976 )
• spleens contain dysplastic erythroid progenitors 45 weeks post-piPC treatment
increased mean corpuscular volume ( J:234976 )
• observed at 45 weeks post-pIPC injection
• phenotype is increased in severity as compared to mice carrying only the Sf3b1tm1.1Mdf allele
macrocytosis ( J:234976 )
• post-pIPC treatment
increased granulocyte number ( J:234976 )
• increased percentage of granulocytes in peripheral blood and bone marrow at 45 weeks post-pIPC
decreased B cell number ( J:234976 )
• decrease in percentage of B cells in the spleen and bone marrow 45 weeks post-pIPC
increased hematopoietic stem cell number ( J:234976 )
• increase in long term repopulating hematopoietic stem cells (LT-HSC) at 12 and 45 weeks as compared to wild-type
• increase in multi-potent progenitors (MPP) in bone marrow 12 weeks post-piPC treatment

immune system
enlarged spleen ( J:234976 )
• post-piPC treatment
abnormal myelopoiesis ( J:234976 )
• transplantation of bone marrow from mutants into lethally irradiated CD45.1 recipient mice that were treated with pIPC results in increasing (46.5% to 90%) donor chimerism beginning at 16 weeks post transplantation as compared to mice carrying only the Sf3b1tm1.1Mdf allele and wild-type
increased granulocyte number ( J:234976 )
• increased percentage of granulocytes in peripheral blood and bone marrow at 45 weeks post-pIPC
decreased B cell number ( J:234976 )
• decrease in percentage of B cells in the spleen and bone marrow 45 weeks post-pIPC

growth/size/body
enlarged spleen ( J:234976 )
• post-piPC treatment

Mouse Models of Human Disease
 DO ID OMIM ID(s) Ref(s)
myelodysplastic syndrome DOID:0050908 OMIM:614286
 J:234976




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
11/12/2024
MGI 6.24 		The Jackson Laboratory